Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

liraglutide Pen Injector [Saxenda]

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Corresponding author: Sungrae Kim Division of Endocrine and Metabolism, The Catholic University of Korea, Bucheon St. Mary’s… Expand
  • figure 1
  • figure 2
Review
2017
Review
2017
ABSTRACT Obesity is a global epidemic that contributes to a number of health complications including cardiovascular disease, type… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
2016
2016
Obesity is a significant concern in the United States, affecting approximately 35% of the population. Comorbidities, such as… Expand
2016
2016
Obesity is a significant concern in the United States, affecting approximately 35% of the population. Comorbidities, such as… Expand
  • table 1
2015
2015
Liraglutide (Saxenda®; 3 mg dose), a glucagon-like peptide-1 receptor agonist, is indicated as an adjunct to a reduced-calorie… Expand
2015
2015
Despite much advertising to the contrary, there are no dietary supplements that safely and effectively cause weight loss… Expand
  • table 1
  • table 2
Review
2015
Review
2015
Globally, obesity has reached epidemic proportions and poses an ever increasing burden from a societal and healthpayer… Expand
  • table 1
  • figure 1
Review
2015
Review
2015
This article highlights important prescribing information for some drugs that received FDA approval within the past year. These… Expand